Jefferies Reports Incyte's Positive Feedback on Ruxolitinib at EHA

According to a recent report from Jefferies, Incyte (NASDAQ: INCY) has received positive feedback from physicians on ruxolitinib at EHA. After speaking to six physicians regarding their feedback on ruxolitinib, Jefferies remains confident in ruxolitinib's approval and a successful product launch.

In the report, Jefferies said, "Of the six physicians we asked about ruxolitinib use in PV, five physicians were positive on the data in this indication. The one negative Dutch physician expressed the view that she thought it would provide limited incremental benefit for the majority of PV patients."

Incyte closed Friday at $17.57.